Dual interference with novel genes mfgl2 and mTNFR1 ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice.

Our studies and those of many others have implicated hepatocyte necrosis and apoptosis mediated by fibrinogen-like protein-2 (fgl2) prothrombinase and tumor necrosis factor receptor (TNFR) in the development of fulminant viral hepatitis, a disease with a mortality rate greater than 80% in cases lacking immediate organ transplantation. This study was designed to explore the efficacy of dual short hairpin RNA (shRNA) interference with fgl2 and TNFR1 in the treatment of murine hepatitis virus strain 3 (MHV-3)-induced fulminant hepatitis in mice. Plasmids p-mfgl2shRNA and p-mTNFR1shRNA, complementary to the sequences for mfgl2 and mTNFR1, were constructed. Plasmids pEGFP-mfgl2 and pEGFP-mTNFR1 expressing mfgl2-EGFP (enhanced green fluorescent protein) and mTNFR1-EGFP fusion proteins were also constructed to screen the inhibitory effect of p-mfgl2shRNA and p-mTNFR1shRNA on mfgl2 and mTNFR1 expression. Cotransfection of individual shRNA plasmids and pcDNA3.0-mfgl2 and pcDNA3.0-mTNFR1 expression constructs into Chinese hamster ovary (CHO) cells significantly inhibited mfgl2 and mTNFR1 gene expression, as evidenced by fluorescence microscopy, reverse transcription-polymerase chain reaction, and Western blotting. In vivo hydrodynamic delivery of dual-interference shRNA plasmids for mfgl2 and mTNFR1 significantly decreased mfgl2 and mTNFR1 expression; markedly ameliorated fibrin deposition, hepatocyte necrosis, and apoptosis; and prolonged survival against fulminant viral hepatitis induced by MHV-3 in BALB/cJ mice compared with mfgl2 or TNFR1 single-gene interference. These results indicate that in vivo interference with genes for more than one key target provides superior treatment efficacy compared with single-gene interference.

[1]  Monilola A. Olayioye,et al.  Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration. , 2009, Experimental cell research.

[2]  M. He,et al.  RNA interference and antiviral therapy. , 2007, World journal of gastroenterology.

[3]  Q. Ning,et al.  Novel mfgl2 antisense plasmid inhibits murine fgl2 expression and ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice. , 2006, Human gene therapy.

[4]  Q. Ning,et al.  Cytokine-Induced Hepatic Apoptosis Is Dependent on FGL2/Fibroleukin: The Role of Sp1/Sp3 and STAT1/PU.1 Composite cis Elements , 2006, The Journal of Immunology.

[5]  Y. Nakayama,et al.  CTLA‐4Ig suppresses liver injury by inhibiting acquired immune responses in a mouse model of fulminant hepatitis , 2005, Hepatology.

[6]  Sangdun Choi,et al.  Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy , 2005, Nature Biotechnology.

[7]  Mario Stevenson,et al.  Therapeutic potential of RNA interference. , 2004, The New England journal of medicine.

[8]  M. Amarzguioui,et al.  An algorithm for selection of functional siRNA sequences. , 2004, Biochemical and biophysical research communications.

[9]  S. Jayasena,et al.  Functional siRNAs and miRNAs Exhibit Strand Bias , 2003, Cell.

[10]  G. Gores,et al.  Mechanisms of liver injury: an overview. , 2003, Current molecular medicine.

[11]  W. Coleman,et al.  Mechanisms of human hepatocarcinogenesis. , 2003, Current molecular medicine.

[12]  S. Kaneko,et al.  Mechanisms of viral hepatitis induced liver injury. , 2003, Current molecular medicine.

[13]  Anton P. McCaffrey,et al.  A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice , 2003, Hepatology.

[14]  V. Cheng,et al.  Current issues and treatment of fulminant hepatic failure including transplantation in Hong Kong and the Far East. , 2003, Seminars in liver disease.

[15]  Judy Lieberman,et al.  RNA interference targeting Fas protects mice from fulminant hepatitis , 2003, Nature Medicine.

[16]  P. Marsden,et al.  Kinetic Analysis of a Unique Direct Prothrombinase, fgl2, and Identification of a Serine Residue Critical for the Prothrombinase Activity1 , 2002, The Journal of Immunology.

[17]  Jean-Michel Pawlotsky,et al.  Molecular diagnosis of viral hepatitis. , 2002, Gastroenterology.

[18]  C. Ferran,et al.  A20 protects mice from D‐galactosamine/lipopolysaccharide acute toxic lethal hepatitis , 2002, Hepatology.

[19]  S. Rose-John,et al.  Hyper-IL-6 gene therapy reverses fulminant hepatic failure. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  Key‐Sun Kim,et al.  Fas- and Tumor Necrosis Factor-mediated Apoptosis Uses the Same Binding Surface of FADD to Trigger Signal Transduction , 2000, The Journal of Biological Chemistry.

[21]  P. Marsden,et al.  Molecular and Functional Analysis of the Human Prothrombinase Gene (HFGL2) and Its Role in Viral Hepatitis , 2000, The American Journal of Pathology.

[22]  J. Pober,et al.  Recent advances in the molecular basis of TNF signal transduction. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[23]  Ming Liu,et al.  Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. , 1998, Journal of immunology.

[24]  Q. Ning,et al.  Fulminant Hepatic Failure in Murine Hepatitis Virus Strain 3 Infection: Tissue-Specific Expression of a Novel fgl2 Prothrombinase , 1997, Journal of Virology.

[25]  D. Wallach,et al.  A potential mechanism of "cross-talk" between the p55 tumor necrosis factor receptor and Fas/APO1: proteins binding to the death domains of the two receptors also bind to each other , 1996, The Journal of experimental medicine.

[26]  M. Leist,et al.  Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. , 1994, Journal of immunology.

[27]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[28]  T. Mak,et al.  Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection , 1993, Cell.

[29]  S. Chung,et al.  Monoclonal antiprothrombinase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infection , 1992, The Journal of experimental medicine.

[30]  G. Levy,et al.  Murine lymphoid procoagulant activity induced by bacterial lipopolysaccharide and immune complexes is a monocyte prothrombinase , 1982, The Journal of experimental medicine.

[31]  P. Khaw,et al.  Novel antisense oligonucleotides targeting TGF-β inhibit in vivo scarring and improve surgical outcome , 2003, Gene Therapy.

[32]  J. Leibowitz,et al.  Caspase inhibitors block MHV-3 induced apoptosis and enhance viral replication and pathogenicity. , 2001, Advances in Experimental Medicine and Biology.

[33]  Q. Ning,et al.  Expression of the fgl2 and its protein product (prothrombinase) in tissues during murine hepatitis virus strain-3 (MHV-3) infection. , 1998, Advances in experimental medicine and biology.